Compared with placebo, the drug tafamidis (Pfizer) reduces decline in left ventricular (LV) systolic and diastolic function, suggests post hoc analysis of a randomized trial of patients with ...
According to new research, patisiran maintains long-term kidney function in ATTR-PN. Long-term patisiran treatment maintained stable eGFR in patients with ATTR-PN and chronic kidney disease, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback